Evolent Health Q3 net loss attributable to common shareholders narrows 12% to $23.57 million; Q3 revenue rises 51% to $725.37 million

Bitget2026/11/05 12:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evolent Health’s third-quarter 2026 net loss attributable to common shareholders narrowed 12% year-over-year to $23.57 million.
Revenue jumped 51% year-over-year to $725.37 million.
An expanded oncology agreement covers approximately 1 million additional Commercial lives, with services starting January 1, 2027.
Full-year 2026 revenue guidance remained at $2.6 billion to $2.7 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolent Health Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH89433) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evolent Health Q3 net loss attributable to common shareholders narrows 12% to $23.57 million; Q3 revenue rises 51% to $725.37 million

You may also like

Crypto prices